Call Us: 888-488-5750

Facebook Linkedin

Join VativoRx at the 109th OHA Annual Meeting & Education Summit

We are thrilled to announce that VativoRx will attend the 109th Ohio Hospital Association (OHA) Annual Meeting & Education Summit, held from June 10-12, 2024, at the Hilton Columbus at Easton. This premier event brings together healthcare leaders to discuss innovations, strategies, and solutions to improve healthcare delivery in Ohio.

As a proud partner of the OHA, VativoRx is dedicated to supporting hospitals and healthcare facilities in maximizing their financial health through innovative rebate management solutions. Our proprietary platform helps capture post-administration drug rebates, providing a significant revenue boost without interfering with existing Purchasing or GPO front-end rebates, or 340B status.

Did you know? Many drug manufacturers offer rebates on medications post-administration that can significantly boost your revenue. These rebates can be captured seamlessly with VativoRx, offering additional income streams to healthcare facilities.

Notable Speakers:

The conference will feature several distinguished speakers, including industry experts and healthcare leaders, who will share insights on current trends and future directions in healthcare.

We invite you to visit us at Booth #36 to learn more about how VativoRx can help your facility unlock hidden revenue opportunities and enhance financial performance. Our team will be available to discuss tailored solutions that fit your specific needs and demonstrate our commitment to supporting the healthcare community.

Don’t miss this opportunity to network with peers, gain valuable knowledge, and discover how VativoRx can contribute to your organization’s success. See you at the 109th OHA Annual Meeting & Education Summit!

For more details about the event, visit the Ohio Hospital Association Annual Meeting page.

Pharma Tariffs and Specialty Drug Cost Management: What Health Plans and TPAs Should Be Watching

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.

Read More »
April 17, 2026

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »
March 27, 2026